CEA-Leti
Lipidots Platform Strengthens Immune Response to Protein That Is Key to HIV Vaccine; Results Presented in Nature Publishing Group's npj Vaccines . GRENOBLE, France - Feb. Leti, a research institute of CEA Tech, in collaboration with CEA's Fundamental Research Division , has developed a new vaccine approach for HIV based on engineered lipid nanoparticles that deliver p24 - a viral protein that is key to an HIV vaccine- and optimize the CpG adjuvant's effect. Until now, p24-based vaccines have shown limited effectiveness because of an insufficient immune response to this antigen in HIV patients. Based on its Lipidots delivery platform, CEA-Leti's new approach improves immunogenicity against the p24 HIV protein by loading it and an immunostimulant agent onto nanostructured lipid carriers (NLCs). This may be a first step for a new HIV vaccine that also would include additional components of the virus. Lipidots is a versatile nano-delivery platform that encapsulates drugs and/or imaging agents in tiny droplets of oil and delivers them to targeted cells in the body for patient treatment or diagnosis.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
